Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > BLUE bluebird bio > Detailed Quotes

BLUE bluebird bio

Watchlist
6.580
-0.250-3.66%
Close 08/16 16:00 ET
6.600
+0.02+0.30%
Post Mkt Price 08/16 19:59 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
6.855
Open
6.750
Turnover
32.59M
Low
6.430
Pre Close
6.830
Volume
4.92M
Market Cap
507.46M
P/E(TTM)
Loss
52wk High
17.850
Shares
77.12M
P/E(Static)
Loss
52wk Low
2.865
Float Cap
477.41M
Bid/Ask %
50.00%
Historical High
152.883
Shs Float
72.55M
Volume Ratio
0.68
Historical Low
2.865
Dividend TTM
--
Div Yield TTM
450
P/B
2.82
Dividend LFY
--
Div Yield LFY
6838.90%
Turnover Ratio
6.78%
Amplitude
6.22%
Avg Price
6.624
Lot Size
1
Float Cap
477.41M
Bid/Ask %
50.00%
Historical High
152.883
Shs Float
72.55M
Volume Ratio
0.68
Historical Low
2.865
Dividend TTM
--
P/B
2.82
Dividend LFY
--
Turnover Ratio
6.78%
Amplitude
6.22%
Avg Price
6.624
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
CEO: Obenshain, Andrew
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top